guest ::
| Home > Publications Database > The plasma miRNAome in ADNI: Signatures to aid the detection of at-risk individuals. > print |
| Home > Publications Database > The plasma miRNAome in ADNI: Signatures to aid the detection of at-risk individuals. > print |
| 001 | 272963 | ||
| 005 | 20241208000025.0 | ||
| 024 | 7 | _ | |a 10.1002/alz.14157 |2 doi |
| 024 | 7 | _ | |a pmid:39291752 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC11567822 |2 pmc |
| 024 | 7 | _ | |a 1552-5260 |2 ISSN |
| 024 | 7 | _ | |a 1552-5279 |2 ISSN |
| 024 | 7 | _ | |a altmetric:167941683 |2 altmetric |
| 037 | _ | _ | |a DZNE-2024-01342 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Krüger, Dennis M |0 P:(DE-2719)2812548 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a The plasma miRNAome in ADNI: Signatures to aid the detection of at-risk individuals. |
| 260 | _ | _ | |a Hoboken, NJ |c 2024 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1732007277_10207 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a MicroRNAs are short non-coding RNAs that control proteostasis at the systems level and are emerging as potential prognostic and diagnostic biomarkers for Alzheimer's disease (AD).We performed small RNA sequencing on plasma samples from 847 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants.We identified microRNA signatures that correlate with AD diagnoses and help predict the conversion from mild cognitive impairment (MCI) to AD.Our data demonstrate that plasma microRNA signatures can be used to not only diagnose MCI, but also, critically, predict the conversion from MCI to AD. Moreover, combined with neuropsychological testing, plasma microRNAome evaluation helps predict MCI to AD conversion. These findings are of considerable public interest because they provide a path toward reducing indiscriminate utilization of costly and invasive testing by defining the at-risk segment of the aging population.We provide the first analysis of the plasma microRNAome for the ADNI study. The levels of several microRNAs can be used as biomarkers for the prediction of conversion from MCI to AD. Adding the evaluation of plasma microRNA levels to neuropsychological testing in a clinical setting increases the accuracy of MCI to AD conversion prediction. |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 0 |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Alzheimer's disease |2 Other |
| 650 | _ | 7 | |a blood biomarker |2 Other |
| 650 | _ | 7 | |a cognitive decline |2 Other |
| 650 | _ | 7 | |a microRNA |2 Other |
| 650 | _ | 7 | |a mild cognitive impairment |2 Other |
| 650 | _ | 7 | |a plasma |2 Other |
| 650 | _ | 7 | |a small non‐coding RNA |2 Other |
| 650 | _ | 7 | |a MicroRNAs |2 NLM Chemicals |
| 650 | _ | 7 | |a Biomarkers |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: blood |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: genetics |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: diagnosis |2 MeSH |
| 650 | _ | 2 | |a MicroRNAs: blood |2 MeSH |
| 650 | _ | 2 | |a MicroRNAs: genetics |2 MeSH |
| 650 | _ | 2 | |a Cognitive Dysfunction: blood |2 MeSH |
| 650 | _ | 2 | |a Cognitive Dysfunction: genetics |2 MeSH |
| 650 | _ | 2 | |a Cognitive Dysfunction: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Biomarkers: blood |2 MeSH |
| 650 | _ | 2 | |a Neuropsychological Tests: statistics & numerical data |2 MeSH |
| 650 | _ | 2 | |a Disease Progression |2 MeSH |
| 650 | _ | 2 | |a Aged, 80 and over |2 MeSH |
| 650 | _ | 2 | |a Neuroimaging |2 MeSH |
| 700 | 1 | _ | |a Pena Centeno, Tonatiuh |0 P:(DE-2719)2811063 |b 1 |u dzne |
| 700 | 1 | _ | |a Liu, Shiwei |b 2 |
| 700 | 1 | _ | |a Park, Tamina |b 3 |
| 700 | 1 | _ | |a Kaurani, Lalit |0 P:(DE-2719)2812832 |b 4 |u dzne |
| 700 | 1 | _ | |a Pradhan, Ranjit |0 P:(DE-2719)9001438 |b 5 |u dzne |
| 700 | 1 | _ | |a Huang, Yen-Ning |b 6 |
| 700 | 1 | _ | |a Risacher, Shannon L |b 7 |
| 700 | 1 | _ | |a Burkhardt, Susanne |0 P:(DE-2719)2810773 |b 8 |u dzne |
| 700 | 1 | _ | |a Schütz, Anna-Lena |0 P:(DE-2719)2810585 |b 9 |u dzne |
| 700 | 1 | _ | |a Wan, Yang |b 10 |
| 700 | 1 | _ | |a Shaw, Leslie M |b 11 |
| 700 | 1 | _ | |a Brodsky, Alexander S |b 12 |
| 700 | 1 | _ | |a DeStefano, Anita L |b 13 |
| 700 | 1 | _ | |a Lin, Honghuang |b 14 |
| 700 | 1 | _ | |a Schroeder, Robert |0 P:(DE-HGF)0 |b 15 |
| 700 | 1 | _ | |a Krunic, Andre |b 16 |
| 700 | 1 | _ | |a Hempel, Nina |0 P:(DE-2719)9003058 |b 17 |u dzne |
| 700 | 1 | _ | |a Sananbenesi, Farahnaz |0 P:(DE-2719)2811099 |b 18 |u dzne |
| 700 | 1 | _ | |a Blusztajn, Jan Krzysztof |b 19 |
| 700 | 1 | _ | |a Saykin, Andrew J |b 20 |
| 700 | 1 | _ | |a Delalle, Ivana |0 0000-0002-1873-3064 |b 21 |
| 700 | 1 | _ | |a Nho, Kwangsik |b 22 |
| 700 | 1 | _ | |a Fischer, Andre |0 P:(DE-2719)2000047 |b 23 |e Last author |u dzne |
| 700 | 1 | _ | |a Initiative, Alzheimer's Disease Neuroimaging |b 24 |e Collaboration Author |
| 773 | _ | _ | |a 10.1002/alz.14157 |g Vol. 20, no. 11, p. 7479 - 7494 |0 PERI:(DE-600)2201940-6 |n 11 |p 7479 - 7494 |t Alzheimer's and dementia |v 20 |y 2024 |x 1552-5260 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/272963/files/DZNE-2024-01342.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/272963/files/DZNE-2024-01342.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:272963 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2812548 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-2719)2811063 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 4 |6 P:(DE-2719)2812832 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)9001438 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 8 |6 P:(DE-2719)2810773 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 9 |6 P:(DE-2719)2810585 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 15 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 17 |6 P:(DE-2719)9003058 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 18 |6 P:(DE-2719)2811099 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 23 |6 P:(DE-2719)2000047 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 1 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-25 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2023-10-25 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2023-10-25 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-25 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-25 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-25 |
| 920 | 1 | _ | |0 I:(DE-2719)1410002 |k AG Fischer |l Epigenetics and Systems Medicine in Neurodegenerative Diseases |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1440016 |k Bioinformatics Unit (Göttingen) |l Bioinformatics and Genome Dynamics Core (Göttingen) |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1410004 |k AG Sananbenesi |l Genome Dynamics in Neurodegenerative Diseases |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1410002 |
| 980 | _ | _ | |a I:(DE-2719)1440016 |
| 980 | _ | _ | |a I:(DE-2719)1410004 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|